Neuralink’s private-market valuation estimates range from roughly $29 billion to $53 billion as of early October 2026, reflecting strong secondary trading activity after a $650 million Series E at about $9–10 billion in 2025. Recent clinical momentum, including a new 11.32 bits-per-second BCI record, expanded decoder training on over 50,000 hours of unlabeled neural data, reduced calibration times, and additional implants in the U.S. and Canada, has supported trader sentiment around further upside by year-end. Key swing factors include pace of FDA interactions for the Blindsight vision device, enrollment in ongoing motor and speech trials, potential follow-on funding rounds, and competitive pressure from peers such as Precision Neuroscience. Private valuations remain sensitive to milestone announcements and macroeconomic risk appetite through December.